Ultragenyx Pharmaceutical financials at a glance

+ Portfolio

The revenue of Ultragenyx Pharmaceutical is reported as 0.43425 billion Dollars in the fiscal year 2023. The earnings were -8.25 Dollars per share in 2023, which was 16.16 higher than 2022. And about -0.51908 billion Dollars are reported as free cash flow in the financials of Ultragenyx Pharmaceutical 2023. No dividends were paid to the shareholders of the Ultragenyx Pharmaceutical stock NasdaqGS:RARE in the financial year 2023.

$434.25M

Revenue

$-8.25

Earnings Per Share

-59.74%

Gross Margin %

$-,510.97M

Free Cash Flow

Revenue

434.25

Earnings Per Share

-8.25

Gross Margin %

-59.74

Free Cash Flow

-,510.97

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Rev.	Revenue	N/A	$434.25M	$363.33M	$351.41M	$271.03M	$103.71M	$51.50M	$2.61M	$0.13M	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	-69.96%	-59.74%	-,102.05%	-46.03%	-54.31%	-,253.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	-,144.51%	-,131.08%	-,178.60%	-,108.63%	-,121.80%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-8.98	$-8.25	$-9.84	$-6.08	$-5.87	$-7.12	$-3.97	$-7.50	$-6.21	$-3.68	$-2.25	$-14.87
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%
Sha.	Shares	N/AM	82.34M	70.22M	69.38M	66.95M	57.89M	51.28M	49.61M	41.73M	38.98M	35.6M	30.04M
OCF	Operating Cash Flow	N/A	$-,474.81M	$-,380.47M	$-,338.70M	$-,132.22M	$-,360.94M	$-,290.57M	$-,253.84M	$-,160.98M	$-,105.98M	$-44.63M	$-31.20M
FCF	Free Cash Flow	N/A	$-,510.97M	$-,496.59M	$-,411.79M	$-,176.13M	$-,370.22M	$-,294.64M	$-,256.64M	$-,171.16M	$-,110.93M	$-46.78M	$-31.61M
FCFS	Free Cash Flow Per Share	$-7.82	$-7.09	$-7.53	$-6.07	$-2.89	$-6.54	$-5.92	$-6.05	$-4.32	$-3.02	$-1.78	$-9.34

Ultragenyx Pharmaceutical financials at a glance

Financials

Discover